ADHD Pharmacotherapy and Mortality in Individuals With ADHD
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Importance: Attention-deficit/hyperactivity disorder (ADHD) is associated with increased risks of adverse health outcomes including premature death, but it is unclear whether ADHD pharmacotherapy influences the mortality risk. Objective: To investigate whether initiation of ADHD pharmacotherapy was associated with reduced mortality risk in individuals with ADHD. Design, Setting, and Participants: In an observational nationwide cohort study in Sweden applying the target trial emulation framework, we identified individuals aged 6 through 64 years with an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation prior to diagnosis. Follow-up started from ADHD diagnosis until death, emigration, 2 years after ADHD diagnosis, or December 31, 2020, whichever came first. Exposures: ADHD medication initiation was defined as dispensing of medication within 3 months of diagnosis. Main Outcomes and Measures: We assessed all-cause mortality within 2 years of ADHD diagnosis, as well as natural-cause (eg, physical conditions) and unnatural-cause mortality (eg, unintentional injuries, suicide, and accidental poisonings). Results: Of 148 578 individuals with ADHD (61 356 females [41.3%]), 84 204 (56.7%) initiated ADHD medication. The median age at diagnosis was 17.4 years (IQR, 11.6-29.1 years). The 2-year mortality risk was lower in the initiation treatment strategy group (39.1 per 10 000 individuals) than in the noninitiation treatment strategy group (48.1 per 10 000 individuals), with a risk difference of −8.9 per 10 000 individuals (95% CI, −17.3 to −0.6). ADHD medication initiation was associated with significantly lower rate of all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.70 to 0.88) and unnatural-cause mortality (2-year mortality risk, 25.9 per 10 000 individuals vs 33.3 per 10 000 individuals; risk difference, −7.4 per 10 000 individuals; 95% CI, −14.2 to −0.5; HR, 0.75; 95% CI, 0.66 to 0.86), but not natural-cause mortality (2-year mortality risk, 13.1 per 10 000 individuals vs 14.7 per 10 000 individuals; risk difference, −1.6 per 10 000 individuals; 95% CI, −6.4 to 3.2; HR, 0.86; 95% CI, 0.71 to 1.05). Conclusions and Relevance: Among individuals diagnosed with ADHD, medication initiation was associated with significantly lower all-cause mortality, particularly for death due to unnatural causes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Mental Health Surveillance Among Children — United States, 2013–2019
Bitsko, R. H., Claussen, A. H., Lichstein, J., Black, L. I., Jones, S. E., Danielson, M. L., Hoenig, J. M., Davis Jack, S. P., Brody, D. J., Gyawali, S., et al. (2022) · MMWR Supplements · doi:10.15585/mmwr.su7102a1 · Cited by 1,723
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545
Self-citationBalance diagnostics after propensity score matching
written on behalf of AME Big-Data Clinical Trial Collaborative Group, Zhang, Z., Kim, H. J., Lonjon, G., & Zhu, Y. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.12.10 · Cited by 1,031
Academic and Educational Outcomes of Children With ADHD
Loe, I. M., & Feldman, H. M. (2007) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsl054 · Cited by 951
Hellström (2019) · doi:10.21037/atm · Cited by 798
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. V. (1999) · Pediatrics · doi:10.1542/peds.104.2.e20 · Cited by 493
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Research works printed but not linked: 17
- Arrondo, 2022, Associations between mental and physical conditions in children and adolescents: an umbrella review., Neurosci Biobehav Rev, 137, 10.1016/j.neubiorev.2022.104662 · DOI · Paper page
- Du Rietz, 2021, Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study., Lancet Psychiatry, 8, 774, 10.1016/S2215-0366(21)00171-1 · DOI · Paper page
- Zhang, 2022, Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis., JAMA Netw Open, 5, 10.1001/jamanetworkopen.2022.43597 · DOI · Paper page
- Zhang, 2023, Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases., JAMA Psychiatry
- Chen, 2020, Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study., Br J Psychiatry, 220, 1
- Stricker, 2022, General practice database on mortality in adults on methylphenidate: cohort study., BMJ Open, 12, 10.1136/bmjopen-2021-057303 · DOI
- Li, 2022, Attention-deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population-based cohort study., World Psychiatry, 21, 452, 10.1002/wps.v21.3 · doi:10.1002/wps.v21.3
- Hernán, 2022, Target trial emulation: a framework for causal inference from observational data., JAMA, 328, 2446, 10.1001/jama.2022.21383 · DOI · Paper page
- Khan, 2020, A review of measures used to examine medication adherence in people with ADHD at initiation, implementation and discontinuation of pharmacotherapy., Res Social Adm Pharm, 16, 277, 10.1016/j.sapharm.2019.06.001 · DOI
- Matthews, 2021, Comparing effect estimates in randomized trials and observational studies from the same population: an application to percutaneous coronary intervention., J Am Heart Assoc, 10, 10.1161/JAHA.120.020357 · DOI
- Maringe, 2020, Reflection on modern methods: trial emulation in the presence of immortal-time bias. assessing the benefit of major surgery for elderly lung cancer patients using observational data., Int J Epidemiol, 49, 1719, 10.1093/ije/dyaa057 · DOI · Paper page
- Cain, 2009, Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death., Stat Med, 28, 1725, 10.1002/sim.v28:12 · doi:10.1002/sim.v28:12
- Young, 2020, A causal framework for classical statistical estimands in failure-time settings with competing events., Stat Med, 39, 1199, 10.1002/sim.v39.8 · doi:10.1002/sim.v39.8
- Hallas, 2014, Use of self-controlled designs in pharmacoepidemiology., J Intern Med, 275, 581, 10.1111/joim.2014.275.issue-6 · doi:10.1111/joim.2014.275.issue-6
- Langan, 2018, The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)., BMJ, 363, k3532, 10.1136/bmj.k3532 · DOI · Paper page
- Liang, 2018, Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study., Res Dev Disabil, 72, 96, 10.1016/j.ridd.2017.10.023 · DOI · Paper page
- Xu, 2019, Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis., Eur J Endocrinol, 180, 243, 10.1530/EJE-18-0792 · DOI · Paper page
Cited by
Staley, B. S., Robinson, L. R., Claussen, A. H., Katz, S. M., Danielson, M. L., Summers, A. D., Farr, S. L., Blumberg, S. J., & Tinker, S. C. (2024) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7340a1 · Cited by 93
Platania, N. M., Starreveld, D. E. J., Wynchank, D., Beekman, A. T. F., & Kooij, S. (2025) · Frontiers in Global Women's Health · doi:10.3389/fgwh.2025.1549028 · Cited by 27
ADHD in Adulthood: Clinical Presentation, Comorbidities, and Treatment Perspectives
Bogdańska-Chomczyk, E., Majewski, M. K., & Kozłowska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211020 · Cited by 15
“These diets aim to reduce systemic inflammation and identify food-based symptom triggers [185].”
Faraone, S. V., Ward, C. L., Boucher, M., Elbekai, R., & Brunner, E. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106275 · Cited by 10
“…(academic or occupational) (Varrasi et al., 2023), antisocial behavior and substance abuse (Retz et al., 2021; Van de Glind et al., 2020), a range of psychiatric and somatic comorbidities (Faraone et al., 2024; Choi et al., 2022; Instanes et al., 2018), and premature mortality (Li et al., 2024).”
Child and adolescent psychiatry: challenges, solutions, opportunities, and future directions
Cortese, S., Arango, C., Aymerich, C., Catalan, A., Chetouani, M., Cohen, D., Coghill, D., Gabellone, A., Iniesta, R., Kadan, A., et al. (2026) · World Psychiatry · doi:10.1002/wps.70044 · Cited by 4
Self-citation
Metadata
- Authors
- Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D’Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-03-12
- Volume
- 331
- Issue
- 10
- Pages
- 850
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4392702193
- Cited by
- 124
- References
- 22
- FWCI
- 33.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ADHD Pharmacotherapy and Mortality in Individuals With ADHD. https://app.cochat.ai/papers/10.1001/jama.2024.0851
- The paper
- Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D’Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z. (2024). ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA. https://doi.org/10.1001/jama.2024.0851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.